SCHEMBL4664366

SCHEMBL4664366

Cn1ccc2cc(-c3cc(Nc4ccc(NS(=O)(=O)c5c(F)cccc5F)cc4)ncn3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 8/20 0.45
BCR P11274 7/20 0.45
USP2 O75604 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
CLK4 Q9HAZ1 2/20 0.45
TSHR P16473 1/20 0.45
PKM P14618 2/20 0.41
PKLR P30613 1/20 0.41
FAAH O00519 2/20 0.41
PRF1 P14222 1/20 0.41
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
BACE1 P56817 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667461 0.90 PRF1 (0.46) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4665741 0.87 BPTF (0.49)
SCHEMBL4663918 0.85 BPTF (0.51) USP2CYP1A2CYP3A4CYP2D6CYP2C9
Formic Acid SCHEMBL4665819 0.82 HTR6 (0.46) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4667395 0.82 CYP1A2 (0.46) ABL1BCRUSP2CYP1A2CYP3A4
Formic Acid SCHEMBL4666168 0.82 ABL1 (0.38) ABL1BCRUSP2CYP1A2CYP3A4
Formic Acid SCHEMBL4663890 0.81 PRF1 (0.45) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4665773 0.81 CYP1A2 (0.56) ABL1BCRUSP2CYP1A2CYP3A4
Formic Acid SCHEMBL4667467 0.81 HTR6 (0.41) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4664365 0.81 FAAH (0.49) ABL1BCRTSHRPKMFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885USP2 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.